Morning

About Us

At Highland Therapeutics we use proprietary drug-delivery technology to develop improved versions of existing drug products.

Leadership


David Lickrish

President & Chief Executive Officer

David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Highland Therapeutics.

Under his leadership, Highland has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and two late-stage drugs under development.

Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.

Nelson Isabel

Chief Financial Officer

Nelson Isabel serves as the Company’s Chief Financial Officer.

Prior to joining Highland, Mr. Isabel spent seven years at Biovail Corporation (now Valeant Pharmaceuticals International, Inc.), Canada’s largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.

Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.

David Lickrish

President & Chief Executive Officer

David Lickrish is the co-inventor, founding shareholder and Chief Executive Officer of Ironshore Pharmaceuticals & Development, Inc.

Under his leadership, Ironshore has grown from a start-up company, founded in the midst of the financial crisis, to an international pharmaceutical company with a proprietary drug-delivery technology and two late-stage drugs under development.

Mr. Lickrish studied Microbiology and Finance at the University of Guelph in Canada. He graduated with Honors and received his Bachelor of Commerce in International Economics and Finance. Mr. Lickrish has been a CFA Charter holder since 2001 and has worked internationally covering the Global Pharmaceutical Industry as Senior Vice President of Equity Research.

Nelson Isabel

Chief Financial Officer

Nelson Isabel serves as the Company’s Chief Financial Officer.

Prior to joining Ironshore, Mr. Isabel spent seven years at Biovail Corporation (now Valeant Pharmaceuticals International, Inc.), Canada’s largest publicly traded pharmaceutical company, where he served on its Finance Leadership Team and was responsible for all investor relations and corporate communication activities. Prior to Biovail, Mr. Isabel was an equity research analyst covering the Canadian healthcare industry with CIBC World Markets and with Desjardins Securities.

Mr. Isabel has a B.Sc. in Experimental Animal Physiology and a Master of Business Administration from the Schulich School of Business in Toronto. He has been a CFA Charter holder since 2002.

Dr. Bev Incledon

Executive Vice President, Research & Development

Fiona McDougall

Senior Vice President, Operations

Dr. Randy Sallee

Chief Medical Officer

What We Do


Highland Therapeutics Inc. is a Toronto-based pharmaceutical company whose wholly owned subsidiaries are focused on the development and commercialization of novel drugs utilizing the DELEXIS® drug delivery technology platform. DELEXIS® is a proprietary technology developed by Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland, that allows for the nighttime delivery of medicines, with the object of achieving a therapeutic effect immediately upon wakening and throughout the day.

Ironshore’s lead compound, HLD200 (delayed-release and extended-release methylphenidate), is under development for the treatment of Attention-Deficit/Hyperactivity Disorder, or ADHD. A New Drug Application has been submitted to the U.S FDA.

HLD100, also under development for the treatment of ADHD, is expected to begin a pivotal Phase 3 trial in H2/2017.

Our Office

Highland Office

Highland Pharmaceuticals

MaRS Centre, South Tower
101 College St., Suite 200
Toronto, ON M5G 1L7

Ironshore Pharmaceuticals

Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., is a pharmaceutical company that is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. Visit ironshorepharma.com for more information.

Ironshore Office

Controlled Release

Ironshore in the Cayman Islands

Research & Development Headquarters
10 Market Street
Suite 715
Camana Bay, KY1-9006
Cayman Islands

Community Support


MaRS Building

Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

> Discover MaRS